£414K
The funding round was backed by Co Angel, The North West Fund for Biomedical, and the Central Manchester Foundation Trust.
G
Gelexir
Gelexir develops an injectable hydrogel to treat back pain and reduce the need for surgery.
Manchester, UK
£414KTotal raised
Gelexir is a University of Manchester spinout that has developed an injectable hydrogel designed to relieve back pain and potentially replace invasive spinal surgery.
Categories
Team
PJ
Hv
Hans von Celsing
Executive director
Hans serves as chairman of the board at several companies, including CLS, Oscar Properties Holdings, and Partner Fondkommission. He also holds non-executive and executive director roles across healthcare and investment firms.
LinkedIn